Finn's Take· TL;DRIn the United States, colorectal cancer diagnosis rates among people younger than 50 rose 2.9 percent per year from 2013 through 2022, according to the American Cancer Society. That alarming trend has left doctors and researchers searching for answers — not just about why more young people are getting the disease, but why it so often seems to hit them harder. Now, a major new study is beginning to shed light on the biology behind that question.
Dana-Farber Cancer Institute researchers, along with Mass General Brigham researchers from the Gene Lay Institute of Immunology and Inflammation and the Broad Institute, have uncovered biological clues to why colorectal cancer can behave more aggressively in younger people. Published in Nature Medicine, the study — the largest of its kind — lays a foundation for understanding age-associated differences in colorectal cancer and exploring future treatments. And the findings carry real weight: the American Cancer Society's 2026 report identifies colorectal cancer as the leading cause of cancer death in adults under 50.
Researchers analyzed 189 tumors from patients ages 29 to 90 and older, including 54 diagnosed before age 50 and 135 diagnosed at age 50 or older. They measured gene activity in hundreds of thousands of cells and found patterns linked to chemotherapy resistance. The scale and depth of the analysis is what makes this study stand out from prior efforts.
Among tumors of the most common colorectal cancer subtype, younger patients' tumors had significantly more connective and supporting cells than cancer cells — a finding that has been linked to chemotherapy resistance in several types of solid cancer. In other words, the very structure of these tumors may be making them harder to treat. Researchers also saw gene activity suggesting stronger signaling between cells that can help cancer cells move and invade nearby tissue in younger patients. Additionally, researchers found RNA differences in tumors from younger patients — differences in the molecules that carry genetic instructions within cells — some of which appeared repeatedly across different cancer cell types.
"Through Dana-Farber's Young-Onset Colorectal Cancer Center, we see how profoundly this disease can affect younger patients and their families, often during the busiest and most formative years of life," said co-senior author Kimmie Ng, MD, MPH, who is the director of the Young-Onset Colorectal Cancer Center at Dana-Farber. For patients like Kristen Vincent of Orleans, who was just 37 years old when she learned she had stage 3 colorectal cancer, research like this represents a meaningful step toward answers that have been a long time coming.
While the researchers described their work as providing "key insight" into tumors in young individuals, they said it does not yet offer proof linking the differences to more aggressive disease. The findings do not yet explain why more young people are developing colorectal cancer, but researchers say they provide new avenues to investigate and could eventually lead to treatments specifically designed for younger patients. That distinction matters — science rarely delivers a single eureka moment, and this study is best understood as a critical piece of a much larger puzzle.
Updates to screening guidelines for colorectal cancer in the U.S. were already prompted by rising incidence in younger adults: the recommended age of colorectal cancer screening changed from 50 years and older to 45 years and older in 2021. But screening alone can't solve the problem of why these cancers behave differently once they develop. That's where this research steps in.
"While we're still at the beginning of understanding what these differences mean, our work gives researchers a new direction to pursue in tackling this urgent problem in human disease," said study co-author Ana Anderson of Harvard Medical School. With a clearer biological map of how these tumors differ from those in older patients, scientists can now begin designing therapies that target those specific vulnerabilities — rather than relying on treatments built around a disease that looks quite different in a 35-year-old than it does in a 65-year-old.